This study looks at two treatments for colorectal cancer, which affects the colon or rectum. Participants have a specific type of cancer called KRAS/NRAS and BRAF wild-type, which means their cancer does not have certain genetic mutations. The study compares two groups: one group will receive a new drug called amivantamab along with a chemotherapy mix called FOLFIRI (includes 5-fluorouracil, leucovorin, and irinotecan); the other group will receive either cetuximab or bevacizumab with FOLFIRI. Researchers will observe how long it takes for the cancer to progress and how long participants live.
- Study Duration: Participants will be monitored over several months.
- Visits Needed: Regular visits to the study center are required.
- Risks: Possibility of side effects from the drugs, like allergies or lung issues.
How understandable was the trial content above?
Hard to understand
Easy to understand